Fysicon receives CE mark approval for QMAPP, world’s smallest hemodynamic monitoring system

QMAPPoffers cardiologists the most advanced technology available in hemodynamic monitoring.

Oss, Netherlands, 18th July, 2016
Fysicon, the Dutch developer and manufacturer of medical solutions, today announced that it has received CE Mark approval for QMAPP, and complies with the essential requirements of the relevant European health, safety and environmental protection legislation. FDA approval expected in November 2016.

The QMAPP amplifier is the small size of a ream of A4 paper, features all available vital monitoring parameters and has up to 32 bipolar intra-cardiac channels for electrophysiology procedures. QMAPP is perfectly suitable for today’s hybrid rooms, but also for combined and dedicated (cardiac) catheterization labs. QMAPP is fanless which involves no noise and minimizes the risk of cross contamination. The hardware design of QMAPP ensures a high level of usability. Connected via one single cable and mounted to the DIN-Rail of the X-Ray or operating table with a clamp.

Invented, developed & produced in the Netherlands
“We are pleased to announce the CE Mark and look forward to introducing QMAPP in Europe, beginning with commercialization efforts in partnership with our distributors”, said Bert Elberse, CEO.

About Fysicon
Privately held since its formation in 1995, Fysicon develops, manufactures and markets innovative medical technologies in the areas of structural heart disease and critical care monitoring.

ce mark approval qmapp